Inmune Bio Inc reports a Return on Equity (ROE) of -211.99%.

What is INMB's dividend yield?

Inmune Bio Inc offers a dividend yield of 0.00%.

What is INMB's Quality Score?

Our AI rates INMB's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy INMB?

Our AI Timing Score for INMB is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does INMB belong to?

Inmune Bio Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Inmune Bio Inc (INMB) Stock Price, Quality Score & AI Analysis

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

INMB AI Analysis Summary

Our AI summary for INMB: Inmune Bio Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -211.99%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

INMB

Inmune Bio Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 85

USD 1.75

-0.02 (-1.13%) Day Change

Watchlist Portfolio Compare Chart

0.04

D/E

-212.0%

ROE

-161.1%

ROA

0.00%

Div Yield

INMUNE BIO INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.75 Price -0.02 (-1.13%) Day Change	NEWS SCORE: 85

INMB, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	85
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.75
PBV / Sector	2.40 / 5.20
Earning Per Share	-1.55

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	1.23 M GREAT
Average 1W Daily Value	0.31 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.71
NPM Average (%) / Sector	-104,867.84 / -1,721.76
NPM Change Average (%) / Sector	358.98 / 5,211.62 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-161.13 / 27.02
ROA Average (%) / Sector	-99.43 / -368.17
ROA Change Average (%) / Sector	49.83 / 5,404.12 GREAT
ROE (%) / Sector	-211.99 / 3.47
ROE Average (%) / Sector	-132.94 / 6.51
ROE Change Average (%) / Sector	47.30 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:01
Symbol	INMB
Name	INMUNE BIO INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	26.59 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	47.06 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 225 NE Mizner Blvd., Boca Raton, FL, United States, 33432

Phone: 561 710 0512

Website: https://www.inmunebio.com

Sector: Healthcare >> Biotechnology

Description: INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.